Sunshine Biopharma ( (SBFM) ) has issued an announcement.
Sunshine Biopharma Inc. announced a $2.46 million registered direct offering with institutional investors, priced at the market under Nasdaq rules. The offering involves the sale of shares of Common Stock and pre-funded warrants, with proceeds intended for general corporate purposes and working capital. This financial move is expected to support the company’s ongoing operations and enhance its market position in the pharmaceutical industry.
More about Sunshine Biopharma
Sunshine Biopharma Inc. is a pharmaceutical company that offers and researches life-saving medicines across various therapeutic areas, including oncology and antivirals. The company has 70 generic prescription drugs available in Canada and plans to launch 13 additional drugs in 2025. Among these is NIOPEG®, a biosimilar of NEULASTA®, aimed at reducing infection incidence in patients undergoing anti-neoplastic therapy. Sunshine Biopharma is also involved in proprietary drug development, focusing on K1.1 mRNA for liver cancer and PLpro protease inhibitor for SARS Coronavirus infections.
YTD Price Performance: -28.12%
Average Trading Volume: 1,210,546
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.63M
Find detailed analytics on SBFM stock on TipRanks’ Stock Analysis page.